BioAtla (BCAB) announced that its President, Scott Smith, will be leaving the Company to pursue a new opportunity as CEO at Viatris (VTRS). Scott will continue his relationship with BioAtla by serving as a Board of Directors member for the Company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BCAB:
- BioAtla Announces Change in Executive Leadership
- BioAtla announces FDA clearance of IND for BA3182
- BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma
- BioAtla provides clinical program updates, 2023 milestones
- BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones